Endoglin is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells.

Junhui Hu,Wei Guan,Peijun Liu,Jin Dai,Kun Tang,Haibing Xiao,Yuan Qian,Allison C Sharrow,Zhangqun Ye,Lily Wu,Hua Xu
DOI: https://doi.org/10.1016/j.stemcr.2017.07.009
2017-01-01
Stem Cell Reports
Abstract:Renal cell carcinoma (RCC) is a deadly malignancy due to its tendency to metastasize and resistance to chemotherapy. Stem-like tumor cells often confer these aggressive behaviors. We discovered an endoglin (CD105)-expressing subpopulation in human RCC xenografts and patient samples with a greater capability to form spheres in vitro and tumors in mice at low dilutions than parental cells. Knockdown of CD105 by short hairpin RNA and CRISPR/cas9 reduced stemness markers and sphere-formation ability while accelerating senescence in vitro. Importantly, downregulation of CD105 significantly decreased the tumorigenicity and gemcitabine resistance. This loss of stem-like properties can be rescued by CDA, MYC, or NANOG, and CDA might act as a demethylase maintaining MYC and NANOG. In this study, we showed that Endoglin (CD105) expression not only demarcates a cancer stem cell subpopulation but also confers self-renewal ability and contributes to chemoresistance in RCC.
What problem does this paper attempt to address?